News
Fierce Pharma Asia—GSK's massive Hengrui deal; Takeda's revenue drop; Celltrion's major US plant buy
GSK signed a 12-asset licensing deal with Hengrui Pharma. Generic erosion on Vyvanse continued to hurt Takeda. Celltrion is ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback